Logo American Journal of Case Reports

Call: 1.631.629.4328
Mon-Fri 10 am - 2 pm EST

Contact Us

Logo American Journal of Case Reports Logo American Journal of Case Reports Logo American Journal of Case Reports

17 October 2017: Articles  USA

Short-Term High-Dose Steroid Therapy in a Case of Rhabdomyolysis Refractory to Intravenous Fluids

Unusual or unexpected effect of treatment

Fnu Zarlasht EF 1*, Mashal Salehi EF 2, Alamgir Sattar E 1, Mohammad Abu-Hishmeh E 1, Muzammil Khan E 2

DOI: 10.12659/AJCR.905196

Am J Case Rep 2017; 18:1110-1113

0 Comments

Abstract

BACKGROUND: Rhabdomyolysis is a syndrome characterized by skeletal muscle breakdown, that involves the release of intracellular contents into the circulation, including creatine kinase (CK), myoglobin, electrolytes, organic acids, and purines. Causes of rhabdomyolysis include trauma, exertion, drugs, and toxins (including alcohol), and electrolyte abnormalities. The treatment of rhabdomyolysis is to remove the cause and use intravenous (IV) fluids. When this treatment strategy fails to work, high-dose IV steroids may be used.

CASE REPORT: We present a case of rhabdomyolysis following the use of 3,4-methylenedioxy-methamphetamine (MDMA) or ‘ecstasy’ with hypophosphatemia, which was found to be refractory to intravenous hydration. In this case, pulsed dosing of steroid therapy was found to be effective.

CONCLUSIONS: Rhabdomyolysis that is refractory to treatment with IV fluids may respond to a short-term, high-dose course of IV steroids.

Keywords: creatine kinase, N-Methyl-3,4-methylenedioxyamphetamine, rhabdomyolysis

Background

Rhabdomyolysis is a syndrome characterized by skeletal muscle necrosis and the release of the intracellular muscle constituents into the circulation. The severity of the illness ranges from an asymptomatic elevation in serum muscle enzymes to life threatening disease associated with raised serum enzymes, electrolyte imbalance, and acute kidney injury [1].

The standard of care is to treat any underlying etiology and provide aggressive intravenous (IV) hydration with crystalloids.

We present a case of a 35-year-old male, who presented with rhabdomyolysis refractory to intravenous fluids. The purpose of presenting this case is to highlight the potential role of intravenous high-dose glucocorticoids in cases of rhabdomyolysis that do not respond to IV fluids.

Case Report

A 35-year-old male African American patient with the history of asthma, epilepsy, anti-social personality disorder, and poly-substance abuse presented with generalized muscle aches and nausea. Patient denied any other symptoms and confirmed use of ethanol, marijuana and 3,4-methylenedioxymethamphetamine(MDMA) or ‘ecstasy’ the night prior to admission. No similar episodes in the past. Patient was not taking any medications at home.

On examination, temperature was 98°F (36.6°C), heart rate 188 bpm, respiratory rate 33 breaths/minute, blood pressure 134/75 and oxygen saturation was 91% on room air. Patient was diaphoretic, agitated and had generalized muscle tenderness. The rest of physical exam was normal. Laboratory results are shown in Table 1. Urine analysis showed clear yellow urine, with a specific gravity of 1.023, hematuria 3+, proteinuria 2+, negative nitrites and leukocyte esterase, WBC 2–5/hpf, and RBC 2–5/hpf. Urine toxicology was positive for cannabinoids and 3, 4-methylenedioxy-methamphetamine (MDMA). Serum alcohol level was negative.

Patient was started on generous IV fluids and had had aggressive electrolyte replacement.

Although the acute renal injury and electrolyte abnormalities resolved on the second day of hospital admission, yet patient continued to complain of generalized muscle aches with persistently elevated creatine kinase (CK) levels (Table 2).

Subsequently patient was given a single IV dose of 1,000 mg methylprednisolone, which resulted in clinical improvement and a significant reduction in serum Ck levels. (Figure 1). Before steroid treatment, serum CK level was 36,650 U/L, serum myoglobin was 1560 mcg/L, and urine myoglobin 4910 mcg/L. At 12 hours following intravenous steroid therapy, serum CK levels came down to 20,040 U/L, serum myoglobin to 837 mcg/L, and urine myoglobin to 112 mcg/L. At 36 hours following intravenous steroid therapy, serum CK was 4,069 U/L.

Patient was later discharged home with a follow up appointment in medicine clinic which he did not keep.

Discussion

Rhabdomyolysis has many different causes and has been reported following the use of 3,4-methylenedioxy-methamphetamine (MDMA) or ‘ecstasy’ [4–8]. Unlike other drugs, MDMA demonstrates a pattern of toxicity that is independent of dose [9]. Possible mechanisms of rhabdomyolysis due to MDMA include extreme exertion, malignant hyperpyrexia, seizures, or because of direct toxic effects of the drug on the muscle cells [9]. Severe hypophosphatemia has also been described as a cause of rhabdomyolysis [10].

The exact mechanism by which hypophosphatemia induces rhabdomyolysis is unclear, but a possible cause is inhibition of conversion of ADP to ATP and resultant deprivation of energy to the muscle fibers, resulting in rhabdomyolysis [11]. Ethanol-induced rhabdomyolysis may develop from the direct toxic effects on the sarcoplasmic reticulum by increasing sodium permeability and disruption of calcium homeostasis or indirectly due to prolonged immobilization and muscle compression caused by altered mental status, loss of consciousness, and coma [12]. Ethanol ingestion is also associated with hypokalemia, and hypophosphatemia, which can predispose the patient to rhabdomyolysis [12]. There are also case reports of rhabdomyolysis due to the use of synthetic marijuana [13,14].

Our patient had four known risk factors for the development of rhabdomyolysis, including the use of MDMA (ecstasy), marijuana, ethanol abuse, and hypophosphatemia, with no other signs or symptoms suggestive of any underlying inflammatory or immunologic disease. This was patient’s first episode of rhabdomyolysis that occurred after illicit drug use. Patient’s signs and symptoms and family history was not supporting an underlying genetic abnormality. We do not know if any of the four risk factors in our patient played any role in making rhabdomyolysis refractory to IV fluids, and responsive to IV corticosteroids.

Irrespective of the underlying cause, management of rhabdomyolysis involves treating the underlying cause, and prevention and treatment of acute kidney injury through generous and aggressive intravenous hydration that will restore volume status, as well as prevent formation and deposition of intratubular renal casts [15]. However, as in this case, some patients do not respond to intravenous hydration alone, and in such cases, high dose intravenous steroids may be beneficial. Other factors causing persistent rhabdomyolysis need to be ruled out first. Although the primary pharmacologic effects of corticosteroids are both immunosuppressive and anti-inflammatory, the exact mechanism of IV steroids in treating rhabdomyolysis is unclear [16].

Literature review shows only a few cases of IV corticosteroid use in treating rhabdomyolysis. Of the reported cases, one is associated with alcohol abuse, 2 cases with cytomegalovirus(CMV) infection and one with exertion [16–20]. The successful use of IV corticosteroids in these cases leads to the hypothesis that muscle damage in rhabdomyolysis is associated with an inflammatory component. One study that compares reported cases of CMV-associated rhabdomyolysis shows that patients who received IV corticosteroids had a comparatively shorter recovery time in terms of clinical improvement and improvement in CK levels [21]. In our patient clinical improvement and laboratory improvement in CK levels occurred in only 36 hours after the administration of IV steroids.

In short, although first-line management for rhabdomyolysis remains generous IV fluid administration, IV corticosteroid may prove beneficial if the patient fails to respond to IV fluids.

Conclusions

This case report, together with previously reported cases, demonstrate that rhabdomyolysis that is refractory to treatment with IV fluids may respond to a short-term, high-dose course of IV steroids.

References:

1.. Torres PA, Helmstetter JA, Kaye AM, Kaye AD, Rhabdomyolysis: Pathogenesis, diagnosis, and treatment: Ochsner Journal, 2015; 15(1); 58-69, pmid: 25829882

2.. Huerta-Alardín AL, Varon J, Marik PE, Bench-to-bedside review: Rhabdomyolysis – an overview for clinicians: Critical Care, 2005; 9(2); 158-69, pmid: 15774072

3.. Cunningham M, Ecstasy-induced rhabdomyolysis and its role in the development of acute renal failure: Intensive Crit Care Nurs, 1997; 13(4); 216-23, pmid: 9355426

4.. Lehmann ED, Thom CH, Croft DN, Delayed severe rhabdomyolysis after taking “ecstasy”: Postgrad Med J, 1995; 71(833); 186-87

5.. Screaton GR, Singer M, Cairns HS, Hyperpyrexia and rhabdomyolysis after MDMA (‘ecstasy’) abuse: Lancet, 1992; 339; 677-78

6.. Henry JA, Jeffreys KJ, Dawling S, Toxicity and deaths from 3, 4-methylenedioxymethamphetamine (‘ecstasy’): Lancet, 1992; 340; 384-87, pmid: 1353554

7.. Fahal IH, Sallomi DF, Yaqoob M, Bell GM, Acute renal failure after ecstasy: BMJ, 1992; 305(6844); 29

8.. Maxwell DL, Polkey MI, Henry JA, Hyponatraemia and catatonic stupor after taking “ecstasy”: BMJ, 1993; 307(6916); 1399, pmid: 7903884

9.. Campbell GA, Rosner MH, The agony of ecstasy: MDMA (3, 4-methylenedioxymethamphetamine) and the kidney: Clin J Am Soc Nephrol, 2008; 3(6); 1852-60, pmid: 18684895

10.. Singhal PC, Kumar A, Desroches L, Prevalence and predictors of rhabdomyolysis in patients with hypophosphatemia: Am J Med, 1992; 92(5); 458-64, pmid: 1580292

11.. Knochel JP, Barcenas C, Cotton JR, Hypophosphatemia and rhabdomyolysis: J Clin Invest, 1978; 62(6); 1240-46, pmid: 748377

12.. Haas CE, Magram Y, Mishra A, Rhabdomyoysis and acute renal failure following an ethanol and diphenhydramine overdose: Ann Pharmacother, 2003; 37; 538-42, pmid: 12659612

13.. Zhao A, Tan M, Maung A, Rhabdomyolysis and acute kidney injury requiring dialysis as a result of concomitant use of atypical neuroleptics and synthetic cannabinoids: Case Rep Nephrol, 2015; 2015; 235982, pmid: 26550500

14.. Adedinsewo DA, Odewole O, Todd T, Acute rhabdomyolysis following synthetic cannabinoid ingestion: N Am J Med Sci, 2016; 8(6); 256-58, pmid: 27500131

15.. Rusyniak DE, Tandy SL, Hekmatyar SK, The role of mitochondrial un-coupling in 3, 4-methylenedioxymethamphetamine-mediated skeletal muscle hyperthermia and rhabdomyolysis: J Pharmacol Exp Ther, 2005; 313(2); 629-39, pmid: 15644431

16.. Antoon JW, Chakraborti C, Corticosteroids in the treatment of alcohol-induced rhabdomyolysis: Mayo Clin Proc, 2011; 86(10); 1005-7, pmid: 21964178

17.. Yasumoto N, Hara M, Kitamoto Y, Cytomegalovirus infection associated with acute pancreatitis, rhabdomyolysis and renal failure: Intern Med, 1992; 31; 426-30, pmid: 1319248

18.. Hirohama D, Shimizu T, Hashimura K, Reversible respiratory failure due to rhabdomyolysis associated with cytomegalovirus infection: Intern Med, 2008; 47(19); 1743-46, pmid: 18827428

19.. Sato K, Yoneda M, Hayashi K, A steroid-responsive case of severe rhabdomyolysis associated with cytomegalovirus infection: Rinsho Shinkeigaku, 2006; 46; 312-16, pmid: 16886796

20.. Brown J, Mitchell S, A complicated case of exertional heat stroke in a military setting with persistent elevation of creatine phosphokinase: Mil Med, 1992; 157(2); 101-3, pmid: 1603384

21.. Gindre H, Féasson L, Auboyer C, Cathébras P, Severe rhabdomyolysis associated with a primary cytomegalovirus infection in an immunocompetent patient: BMJ Case Rep, 2013; 2013 pii: bcr2012008140

In Press

Case report  China

Thrombolytic Therapy After Return of Spontaneous Circulation in Patients With STEMI From Medically Underdev...

Am J Case Rep In Press; DOI: 10.12659/AJCR.949976  

Case report  Greece

Multilevel Laminectomy for Lumbar Spinal Stenosis With Low Back Pain in Achondroplasia: A Case Report

Am J Case Rep In Press; DOI: 10.12659/AJCR.950290  

Case report  Italy

Fractional CO₂ Laser (SCAR3 Scanner) for a Hypertrophic Retracting Cleft Lip Scar: A Case Report

Am J Case Rep In Press; DOI: 10.12659/AJCR.950607  

Case report  Saudi Arabia

Postoperative Corneal Dellen Following PreserFlo MicroShunt: A Case Report

Am J Case Rep In Press; DOI: 10.12659/AJCR.950985  

Most Viewed Current Articles

07 Dec 2021 : Case report  USA 17,691,734

Edwardsiella tarda: A Classic Presentation of a Rare Fatal Infection, with Possible New Background Risk Fac...

DOI :10.12659/AJCR.934347

Am J Case Rep 2021; 22:e934347

06 Dec 2021 : Case report  Brazil 164,491

Lipedema Can Be Treated Non-Surgically: A Report of 5 Cases

DOI :10.12659/AJCR.934406

Am J Case Rep 2021; 22:e934406

21 Jun 2024 : Case report  China (mainland) 113,090

Intracranial Parasitic Fetus in a Living Infant: A Case Study with Surgical Intervention and Prognosis Anal...

DOI :10.12659/AJCR.944371

Am J Case Rep 2024; 25:e944371

0:00

07 Mar 2024 : Case report  USA 59,175

Neurocysticercosis Presenting as Migraine in the United States

DOI :10.12659/AJCR.943133

Am J Case Rep 2024; 25:e943133

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

American Journal of Case Reports eISSN: 1941-5923
American Journal of Case Reports eISSN: 1941-5923